Phase 2 Stomach Cancer Trial, Recruiting NCT07119463 Sponsor: The First Hospital of Jilin University Condition: Stomach Cancer
Back to Stomach Cancer

Phase 2 Stomach Cancer Trial, Recruiting

NCT07119463
Recruiting Phase 2

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • People between 18 and 80 years old who are scheduled to have surgery for stomach cancer
  • People whose stomach cancer has been confirmed by a laboratory tissue test (pathology), regardless of the specific type of stomach cancer
  • People whose cancer has been assessed by a CT scan as being at stage I, II, or III (meaning it has not spread far), and who are having either keyhole (laparoscopic) or open stomach cancer surgery
  • People whose blood protein (albumin) level is at least 30g/L and whose nutrition screening score (NRS-2002) is 2 or lower, indicating nutritional levels are within an acceptable range before surgery
  • People having any type of radical stomach cancer surgery, whether removing part or all of the stomach
  • People who have given their written agreement to take part in the study
  • People whose overall physical fitness for surgery is rated as ASA Class I, II, or III (a standard medical rating scale)
  • People whose general ability to carry out daily activities is rated at 2 or below on the ECOG scale (a standard scale used to measure how cancer affects daily living)

Who may not be able to join:

  • People who have an active infection or acute complication before surgery, such as pneumonia, urinary tract infection, gastrointestinal bleeding, a perforation, or a bowel blockage
  • People with a weakened immune system, including those who have been taking immune-suppressing medicines (such as steroids) long-term, people who have had an organ transplant, or people diagnosed with HIV
  • People with serious underlying health conditions, such as severe liver disease (Child-Pugh Class B or C), kidney problems with creatinine levels above 133 umol/L, severe heart failure (NYHA Class III or above), or severe lung problems where oxygen levels in the blood are too low (PaO2 at or below 60mmHg) (confirm with trial site)
  • People who have a known allergy to albumin (a blood protein product)
  • People who lose more than 500ml of blood during surgery
  • People whose haemoglobin (a measure of red blood cells) is below 70g/L before surgery
  • People who have received radiation therapy (radiotherapy) before surgery as part of their cancer treatment
  • People who need additional organs removed at the same time as their stomach surgery
  • People in whom cancer is found to have spread to distant parts of the body during surgery, or where complete removal of the cancer is not possible

Reasons a person may be withdrawn from the trial after joining:

  • If a serious allergic reaction to the albumin infusion occurs during the trial, such as severe shock, airway swelling, or dangerously low blood pressure
  • If a participant decides at any point that they no longer wish to continue taking part, their wishes will be respected and their participation will end

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 21 July 2026
Phase 2: approximately ~30% of drugs entering this phase reach regulatory approval, based on published industry-wide historical data. This is not specific to this trial.
Phase success rates shown are historical industry-wide averages based on published data. They are not a prediction for this specific trial or your individual situation.

Contact this trial

Principal Investigator: Yuchen Guo, Ph.D., The First Hospital of Jilin University

Phone: 0086+13630598312

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Phase 2
Sponsor
The First Hospital of Jilin University
Registry
ClinicalTrials.gov
Start date
29 October 2024
Est. completion
1 June 2026

Where this trial is recruiting

🇨🇳 China

Primary endpoints

Incidence of Postoperative Complications (Clavien-Dindo Grade III or Above)

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 21 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov